Feature | April 01, 2013

Rox Medical Enrolls First U.K. Patients in CONTROL-HTN Hypertension Trial

April 1, 2013 — Rox Medical announced enrollment of the first U.K. patients in the CONTROL-HTN international randomized controlled trial of the Rox Flow procedure for the treatment of resistant hypertension. The first patients were enrolled at Eastbourne General Hospital, East Sussex, U.K. by doctors Neil Sulke and Stephan Furniss. For the two patients randomized to treatment, the Rox procedure was performed in the cardiac cath lab in under one hour.

"It was a very enjoyable and straightforward procedure on a patient with very difficult to control blood pressure," said Furniss. "The procedure was relatively painless and the patient showed significant improvement in blood pressure right after the procedure that we'll be anxious to monitor over the coming weeks and months. "This could be a very important new device treatment option for resistant hypertension patients," said Furniss. "We are anxious to enroll additional patients into this exciting trial."

"We like the fact that the Rox procedure is reversible and that it can treat patients who are not candidates or don't seem to respond to renal denervation," added Sulke. 

Rox Medical's Flow procedure is a minimally invasive, catheter procedure to place a small coupler between the artery and vein in the upper leg. The procedure reduces peripheral vascular resistance and by diverting some arterial blood to the veins, adds lost compliance back into the vascular system. Uniquely, the Flow procedure only involves vascular structures away from vital organs like the kidneys, has an immediate effect and is fully reversible. The procedure also does not require heavy pain medications common to renal ablation techniques. The Rox procedure holds the promise of a meaningful long-term reduction in hypertension that may be combined with other device hypertension therapies.

The Rox Flow procedure for hypertension is not approved for use in the United States.

For more information: www.roxmedical.com

 

 

 

Related Content

Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Text Messaging Could Help Tackle High Blood Pressure in At-Risk Patients

Image courtesy of Michigan Medicine

News | Hypertension| September 06, 2017
A new National Institutes of Health-funded hypertension trial will examine the possibility of using an emergency...
SPYRAL HTN-OFF MED Study Results Show Efficacy, Safety of Renal Denervation
News | Renal Denervation| August 31, 2017
Medtronic plc announced its intent to move forward with a new renal denervation pivotal trial following positive first...
MobiusHD Device Shows Promise in Treatment of Resistant Hypertension
News | Hypertension| August 30, 2017
Vascular Dynamics Inc. announced interim results of the company’s first-in-human trial of its MobiusHD implant...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
USC Study Finds Potassium-Rich Diet Can Lower Blood Pressure
News | Hypertension| April 19, 2017
Eating potassium-rich foods like sweet potatoes, avocados, spinach, beans, bananas and even coffee could be key to...
Vascular Dynamics Completes $10.4 Million Financing for MobiusHD System
News | Hypertension| April 13, 2017
Vascular Dynamics Inc. (VDI) a privately held medical device company developing novel solutions for the treatment of...
online lifestyle intervention, systolic blood pressure, hypertension, ACC.17, clinical study
News | Hypertension| March 27, 2017
Participants in Web-based lifestyle counseling reduced their systolic blood pressure by 10 mmHg, compared with a 6 mmHg...
News | Hypertension| February 13, 2017
Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s...
Overlay Init